CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 67 enrolled
Drug / intervention
Echinacea purpurea product +2 morebiological
Likely dose
Echinacea purpurea product 5 mlfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01129128
NCT01129128N/ACompleted

3-arm Randomized Controlled Trial Assessing the in Vivo Effect of an Echinacea Purpurea on Immune Markers in Adults

University of Washington·interventional·Posted May 24, 2010·Updated Jun 21, 2012

In Brief

A clinical study evaluating Echinacea purpurea product and Placebo for Upper Respiratory Tract Infections. Completed, enrolled 67 participants across 1 site.

Detailed Summary

The goal of this study is to determine if either of two, commercially available, Echinacea purpurea products stimulate the immune system. For the study, 60 healthy adults will be randomized to receive one of the two Echinacea purpurea products or placebo for 10 days. Blood will be drawn to assess immune markers just before beginning the study medication, during the 10 day course of medication and after completing the course of medication. It is postulated that adults receiving either of the Echinacea products will have evidence of immune stimulation and those receiving placebo will not.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 24, 2010
Enrollment StartMay 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.1 years ago

Interventions

Echinacea purpurea productbiological

5 ml by mouth 3 times per day for 10 days

Echinacea purpurea productbiological

1 ml by mouth 3 times per day for 10 days

Placebobiological

either 5 ml or 1 ml by mouth three times per day for 10 days